EUVIMED · CrossrefJournal
JAMA Oncology
ISSN 2374-2437 · American Medical Association (AMA)
Latest articles
Modest Individual Gains, Meaningful Population Effect
Chest Computed Tomography Receipt Beyond 5 Years After Lung Cancer Diagnosis and Survival
Computed Tomography Screening and Small Cell Lung Cancer Stage Shift and Survival
Sedation and End-of-Life Delirium, Restfulness, and Agitation
Why Harmonizing NGS Panels Is the Missing Link in Precision Oncology—One Genome, Too Many Standards
Integrating Chemotherapy With Immunotherapy Prior to Surgery for Patients With Locally Advanced HNSCC
Late Recurrence After Radiotherapy Omission in Younger Postmenopausal Patients With Breast Cancer
Early vs Routine Oral Nutritional Supplementation During Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma
A Hypervascular Cervical Mass in an Adolescent Girl
Perioperative Camrelizumab Plus Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
Early vs Routine Oral Nutritional Supplementation During Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma
Global Proposal for the TNM Staging System for Poorly Differentiated Thyroid Cancer
HB0025, a Novel Anti–PD-L1/VEGF Trap Bispecific Antibody Plus Chemotherapy in Advanced Non–Small Cell Lung Cancer
HB0025 With Chemotherapy for Advanced Non–Small Cell Lung Cancer
Evolving First-Line Treatment Strategies in ERBB2 -Positive Metastatic Breast Cancer
Human Leukocyte Antigen Fairness in Novel T-Cell Receptor Therapies
Prognostic vs Predictive Value of ctDNA for Chemotherapy Planning and Discrepancy in Visual Presentation of Overall Survival
Prognostic vs Predictive Value of ctDNA for Chemotherapy Planning and Discrepancy in Visual Presentation of Overall Survival
Prognostic vs Predictive Value of ctDNA for Chemotherapy Planning and Discrepancy in Visual Presentation of Overall Survival
Prognostic vs Predictive Value of ctDNA for Chemotherapy Planning and Discrepancy in Visual Presentation of Overall Survival—Reply
Trends in Racial and Ethnic Representation in the Oncology Trainee Workforce
Errors in Abstract, Key Points, Text, Figure 4, and Supplement 1
Error in Figure 2
Change to Open Access Status
Benmelstobart With or Without Anlotinib After Chemoradiotherapy for Unresectable Non−Small Cell Lung Cancer
FGFR Alterations in Bladder Cancer—From Molecular Pathogenesis to Precision Oncology
Global, Regional, and National Burden of Bone Cancers, 1990 to 2023, With Forecasts to 2050
Doing More With Less in Financially Constrained Health Systems
The Price of Hope—A Brazilian Oncologist’s 4 Encounters With Daraxonrasib
EUVIMED